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To the Editor, 
Three reports recently presented clinical data and comments on a 65-year old 
woman in whom hereditary haemorrhagic teleangiectasia (HHT; Osler’s disease) and 
hepatocellular carcinoma (HCC) coincided, leading to listing for liver transplantation 
(LT) (1-3). Consensus existed on the usefulness of LT in patients with HHT, 
particularly when complicated by HCC, but there was debate over the right timing for 
LT in such patients who are usually well besides the complications of vascular 
malformations (VM). The reported case was complicated by the fact that trans-
arterial chemoembolization for HCC is contraindicated in HHT due to a high 
incidence of abscesses. Hence, therapeutic interventions that override the transplant 
list waiting time are needed. 
Dubuis-Girod and Buscarini (3) advocate the use of bevacizumab, an endothelial 
growth factor antibody approved for treating various cancers, as a “bridge-to-
transplant” measure in patients with HHT and hepatic VM according to a trial in which 
20/24 patients with HHT responded to bevacizumab with improvements of cardiac 
index (CI), nose bleeds, and quality of life (4). 
We report on a 72-year old female with HHT and VM (type III) with symptoms of high 
cardiac output, bilateral leg edema, palpitations and cardiac cachexia with a weight 
loss of 7kg/11 months. We started bevacizumab treatment 3 years ago at 5mg/kg for 
6 applications every other week. Treatment was then very well tolerated and all 
symptoms subsided. Cardiac output (CO) decreased from 15.3L/min (CI 9.5L/min/m2) 
to 7.0L/min (4.4L/min/m2), and further improved to 6.5L/min (3.9L/min/m2) 2½ years 
after treatment cessation.  
However, the patient recently complained about similar symptoms as initially, and CO 
and CI were measured at 9.0L/min and 5.5L/min/m2, respectively. We started a 
second course with bevacizumab (5mg/kg) during which the patient developed acute 
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abdominal pain and presented with fever at 39.2°C, leucocytosis 12.100/L, C-reactive 
protein 126mg/L and mild cholestasis. Computed tomography excluded intestinal 
perforation, but showed bilateral intrahepatic portal vein thrombosis (figure 1). Upon 
analgesia, ceftriaxone and nadroparin symptoms improved rapidly, and treatment 
with phenprocoumon was started. 
Our case confirms that bevacizumab can markedly improve cardiac symptoms and 
function in patients with HHT and offers treatment for those not eligible for LT. 
However, bevacizumab may cause serious side effects among which deep vein 
thrombosis has been reported in up to 13% of treated patients in oncology trials (5). 
Although thromboembolic events could predominantly be due to the underlying 
malignancy (6), they should be carefully considered when treating patients with HHT 
for which bevacizumab is not officially approved and for which experience is still 
limited to case series. 
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Figure 1 
CT scan showing bilateral portal vein thrombosis (white arrows). 
